Company Description
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe.
Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.
The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds.
It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL.
The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019.
CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
| Country | Israel |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Yehiel Tal |
Contact Details
Address: 4 Oppenheimer St., 11th Floor Rehovot, L3 74140 Israel | |
| Phone | 972-73-232-5600 |
| Website | collplant.com |
Stock Details
| Ticker Symbol | CLGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001631487 |
| CUSIP Number | 19516R107 |
| ISIN Number | IL0004960188 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Yehiel Tal | Chief Executive Officer and Director |
| Eran Rotem C.P.A. | Deputy Chief Executive Officer and Chief Financial Officer |
| Oren Fahimipoor | Vice President of Operations |
| Dr. Elana Gazal | Vice President of Research and Development |
| Prof. Oded Shoseyov | Founder and Chief Scientist |
| Hadas Dreiher Horowitz | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2024 | 6-K | Report of foreign issuer |
| Apr 4, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 15, 2024 | 6-K | Report of foreign issuer |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 2, 2024 | 6-K | Report of foreign issuer |
| Nov 29, 2023 | 6-K | Report of foreign issuer |
| Nov 1, 2023 | 6-K | Report of foreign issuer |
| Oct 10, 2023 | 6-K | Report of foreign issuer |
| Sep 22, 2023 | 144 | Filing |